EVO
Evotec·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Ample Liquidity
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EVO
Evotec Se
A German developer of small molecule drugs to treat diseases in the areas of neuroscience, pain, and inflammation
Pharmaceutical
12/08/1993
11/04/2021
NASDAQ Stock Exchange
4,827
12-31
Depository Receipts (Ordinary Shares)
Essener Bogen 7, 22419 Hamburg, Germany
--
Evotec SE was established on December 8, 1993 under the laws of Germany. The company is a leading drug discovery and development partner in the pharmaceutical and biotechnology industries. The company's mission is to collaborate with its partners to discover the best and best-in-class medicines for a variety of difficult-to-treat diseases. To this end, they have built a fully integrated next-generation technology platform that they believe will change the way new drugs are discovered. By leveraging the advanced capabilities of their integrated platform, they are able to provide partners with solutions that significantly improve the quality of new drugs while accelerating the drug discovery process and reducing the high consumption costs often associated with the traditional drug discovery process.
Earnings Call
Q1/2025
Estimate EPS--
Actual EPS-0.194328
Estimate Revenue238.31M
Actual Revenue215.90M
Just 2025 Q1: Diverging Narratives on Pipeline Strategy and Innovate Growth
May 07,2025 03:55
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-0.28248
Estimate Revenue235.82M
Actual Revenue201.54M
Evotec's Q2 2025 Earnings Call: Unpacking Contradictions in R&D, Funding, CapEx, and Working Capital
Aug 13,2025 02:51
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EVO has released its 2024 Q1 earnings. EPS was reported at -0.07, versus the expected -0.1, beating expectations. The chart below visualizes how EVO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EVO has released its 2025 Q3 earnings report, with revenue of 192.32M, reflecting a YoY change of -6.67%, and net profit of -50.56M, showing a YoY change of -14.47%. The Sankey diagram below clearly presents EVO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
